Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nevro Corp (NVRO – Research Report) and Ansell (ANSLF – Research Report).

Nevro Corp (NVRO)

RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Nevro Corp on February 10 and set a price target of $5.85. The company’s shares closed last Tuesday at $5.72.

According to TipRanks.com, Chadha is a 4-star analyst with an average return of 3.9% and a 49.3% success rate. Chadha covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Edwards Lifesciences.

Currently, the analyst consensus on Nevro Corp is a Hold with an average price target of $5.64, implying a -1.6% downside from current levels. In a report issued on February 7, Piper Sandler also upgraded the stock to Hold with a $5.85 price target.

Ansell (ANSLF)

RBC Capital analyst Craig Wong-Pan maintained a Buy rating on Ansell on February 10 and set a price target of A$41.00. The company’s shares closed last Friday at $23.39, close to its 52-week high of $23.42.

According to TipRanks.com, Wong-Pan is a 2-star analyst with an average return of 0.0% and a 47.7% success rate. Wong-Pan covers the Healthcare sector, focusing on stocks such as Nanosonics Limited, Ramsay Health Care, and Cochlear Limited.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ansell with a $24.18 average price target, representing a 3.4% upside. In a report issued on January 28, CLSA also upgraded the stock to Buy with a A$38.00 price target.